Vertex Pharmaceuticals
Develops cystic fibrosis medicines, gene-edited cell therapy, and non-opioid pain treatment.
$540.78
After-hours close−0.92 (−0.17%)
At close$541.69(−1.07%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 170.84%Insiders 0.22%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 253.81M · Float 253.23M · 99.8% free float
Institutions13F, as of Jun 30, 2026
1,814 holders · 433.59M shares · 194 new positions · 896 increased · 624 reduced · 137 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Capital World Investors | 26.12M | 10.29% | +746.9K | Aug 12, 2026 |
| BlackRock, Inc. | 24.11M | 9.50% | +139.9K | Aug 7, 2026 |
| Capital Research Global Investors | 19.49M | 7.68% | −1.64M | Aug 12, 2026 |
| Vanguard Capital Management LLC | 16.58M | 6.53% | +67.9K | Aug 13, 2026 |
| State Street Corp | 11.87M | 4.68% | +141.3K | Aug 7, 2026 |
| Invesco Ltd. | 8.04M | 3.17% | +2.71M | Aug 14, 2026 |
| JPMorgan Chase & Co | 6.52M | 2.57% | −515.6K | Aug 12, 2026 |
| Geode Capital Management, LLC | 6.02M | 2.37% | −121.8K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Capital World Investors | 10.10% | 25.70M | 13G | May 14, 2026 ↗ |
| Capital Research Global Investors | 8.30% | 21.14M | 13G | May 14, 2026 ↗ |
| Vanguard Capital Management | 7.49% | 19.04M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Reshma Kewalramani | director, officer: CEO & President | 98.3K | 0.04% | Mar 3, 2026 |
| Amit Sachdev | officer: EVP Chief Patient & Ext Af Off | 66.5K | 0.03% | Jul 23, 2026 |
| Stuart A. Arbuckle | officer: EVP, COO | 63.4K | 0.02% | Jul 2, 2025 |
| Ourania Tatsis | officer: EVP, Chief Reg. & Quality Off. | 53.6K | 0.02% | Jul 23, 2026 |
| Charles F. Jr Wagner | officer: EVP, CO & FO | 47.0K | 0.02% | Feb 26, 2026 |
| Bruce I. Sachs | director | 41.6K | 0.02% | Aug 7, 2025 |
| Jeffrey M. Leiden | director, officer: Executive Chairman | 34.8K | 0.01% | Feb 26, 2026 |
| David Altshuler | officer: EVP, Chief Scientific Officer | 31.1K | 0.01% | Jan 26, 2026 |
| Joy Liu | officer: EVP and Chief Legal Officer | 19.1K | 0.01% | Jul 6, 2026 |
| Edward Morrow III Atkinson | officer: EVP, Chief Technical Ops. Off. | 18.4K | 0.01% | Feb 26, 2026 |
1 ten-percent owner holds 5.38M shares by Form 4, outside the officers-and-directors figure above · 40 people have not refiled in the last 18 months (1.95M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 2, 2026 | Duncan McKechnieofficer: EVP, Chief Commercial Officer | Sale | 1,541 | $519.00 | 11,001 |
| Jul 2, 2026 | Ourania Tatsisofficer: EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $524.99 | 45,321 |
| Jul 1, 2026 | Joy Liuofficer: EVP and Chief Legal Officer | Sale | 828 | $502.71 | 19,131 |
| Jun 26, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 596 | $482.50 | 15,337 |
| Jun 18, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,020 | $462.17 | 15,933 |
| Jun 15, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 4,062 | $450.00 | 16,953 |
| Jun 5, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,745 | $450.00 | 21,015 |
| May 29, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,974 | $450.00 | 22,760 |
| May 15, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,354 | $453.45 | 24,734 |
| May 15, 2026 | Mark E. Bunnageofficer: EVP, Chief Scientific Officer | Sale | 33 | $453.45 | 7,284 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Sen. Alan Armstrong | Purchase | $1,001 – $15,000 | Joint | Mar 27, 2026 | Jul 21, 2026 ↗ |
| Rep. Ro Khanna · CA17 | Purchase | $1,001 – $15,000 | Spouse | Apr 13, 2026 | May 13, 2026 ↗ |